Chordoma research

Our department is a reference center for the treatment of chordomas, and has one of the world’s most extensive track records, with over 350 patients treated since 1996.

The department also participates in a number of research protocols and collaborates with several teams specializing in chordoma research.

Participation in the development of recommendations with the Chordomas Consensus Group

• Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Ann Oncol. 2017 Jun 1;28(6):1230-1242.

Link: https: //www.ncbi.nlm.nih.gov/pubmed/28184416

• Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015 Feb;16(2):e71-83. doi: 10.1016/S1470-2045(14)71190-8.

Link: https: //www.ncbi.nlm.nih.gov/pubmed/25638683

• Anocef, Référentiels Chordomes, January 2018

Link: https: //www.anocef.org/download.php?modele=anocef_referentiel_chordome2018

Collaborations

• Prognostic markers for chordomas: Pr Homa Adle Biassette, Department of Pathological Anatomy, Hôpital Lariboisière
• Xenograft model: UMR 965, Pr Marc Pocard
• Exome and RNAseq sequencing of chordomas, U830, Institut Curie, Pr Olivier Delattre
• Nanoparticle proton therapy of chordomas, ISNO, Institut des sciences Moleculaires d’ORSAY, Pr Sandrine Lacombe
• Texture studies, UMR 1023 Inserm-CEA, Dr Irène Buvat
• Xenograft, LIP Institut Curie, Dr Didier Decaudin
• Metabolomics of chordomas, Pr Izzie Namer, CHU de Starsbourg

Research protocols in collaboration with the Institut Curie

• Co-investigator of the ExoChord study: “Exome and RNAseq sequencing of chordomas”, U830, Institut Curie, Pr Olivier Delattre

• Co-investigator of the Nano-Chord study, “Potentialisation de la protonthérapie par des nanoparticules dans les chordomes”, ISNO, Institut des sciences Moléculaires d’ORSAY, Pr Sandrine Lacombe

• Co-investigator of the TexChord study: Study of texture using PET/CT images, UMR 1023 Inserm-CEA, Dr Irène Buvat

• Co-investigator of the XenoChord study, “Development of an animal model”, LIP Institut Curie, Dr Didier Decaudin

• Co-investigator of the ProtonChord study, PHRC: “ProtonChorde01” Improvement of local control in chordomas of the skull base, mobile spine and sacrum treated by surgery and complement proton therapy targeting hypoxic cells highlighted by PET/CT with [18-FLUOR] Fluoroazomycin-Arabinoside ([18F]FAZA)